- Home
- GMM vs AVTX Comparison
GMM vs AVTX Comparison
Compare GMM & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- AVTX
- Stock Information
- Founded
- GMM 2017
- AVTX 2011
- Country
- GMM China
- AVTX United States
- Employees
- GMM N/A
- AVTX N/A
- Industry
- GMM
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- GMM
- AVTX Health Care
- Exchange
- GMM Nasdaq
- AVTX Nasdaq
- Market Cap
- GMM 70.8M
- AVTX 57.4M
- IPO Year
- GMM 2023
- AVTX 2015
- Fundamental
- Price
- GMM $2.60
- AVTX $4.96
- Analyst Decision
- GMM
- AVTX Strong Buy
- Analyst Count
- GMM 0
- AVTX 7
- Target Price
- GMM N/A
- AVTX $31.00
- AVG Volume (30 Days)
- GMM 11.7K
- AVTX 122.3K
- Earning Date
- GMM 07-11-2025
- AVTX 08-11-2025
- Dividend Yield
- GMM N/A
- AVTX N/A
- EPS Growth
- GMM 62.17
- AVTX N/A
- EPS
- GMM 6.37
- AVTX N/A
- Revenue
- GMM $41,360,953.00
- AVTX $441,000.00
- Revenue This Year
- GMM N/A
- AVTX N/A
- Revenue Next Year
- GMM N/A
- AVTX N/A
- P/E Ratio
- GMM $0.42
- AVTX N/A
- Revenue Growth
- GMM 53.82
- AVTX N/A
- 52 Week Low
- GMM $1.69
- AVTX $3.39
- 52 Week High
- GMM $15.60
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- GMM 46.87
- AVTX 57.49
- Support Level
- GMM $2.46
- AVTX $4.76
- Resistance Level
- GMM $2.77
- AVTX $5.05
- Average True Range (ATR)
- GMM 0.15
- AVTX 0.30
- MACD
- GMM -0.01
- AVTX 0.03
- Stochastic Oscillator
- GMM 37.25
- AVTX 84.75
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).